Investor Relations

Celldex is a clinical stage biotechnology company dedicated to developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with inflammatory diseases and many forms of cancer.

Recent Releases

Date Title and Summary
Toggle Summary Celldex Initiates a Phase 2 Study of Rindopepimut in Patients with Recurrent Glioblastoma including Avastin® Naive and Refractory Populations
Vaccine Targets Patients with EGFRvIII-positive Recurrent Glioblastoma
Toggle Summary Celldex Therapeutics Announces Initiation of Phase 1 Clinical Trial of CDX-301
Celldex Therapeutics Announces Initiation of Phase 1 Clinical Trial of CDX-301 NEEDHAM, Mass. --(BUSINESS WIRE)--Jan. 17, 2012-- Celldex Therapeutics, Inc. (Nasdaq: CLDX) today announced that dosing has initiated in a Phase 1 study of its hematopoietic growth factor, CDX-301, in healthy subjects.

Upcoming Events

Featured Financial Reports

About us

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.

 

Our Pipeline